Navigation Links
Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
Date:1/9/2014

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2014 at 10:00 a.m. PT / 1:00 p.m. ET. Helen Torley, M.B. Ch. B., M.R.C.P., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
2. Public Offerings of Common Stock, Financial Results, and Significant Progress in Key Development Programs - Research Report on BioCryst, Exelixis, Idenix, Puma Biotechnology, and Halozyme
3. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
4. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
5. Halozyme to Host Second Quarter Financial Results Conference Call
6. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
7. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
8. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
9. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
10. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
11. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... -- Rhythm, a biopharmaceutical company developing peptide therapeutics that ... metabolic disorders, announced today that it has filed a ... and Exchange Commission (SEC) relating to the proposed initial ... number of shares to be offered and the price ... Citigroup and Cowen and Company will act ...
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Trifluoroacetic Acid ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... CRY ), a,biomaterials, medical device and tissue processing ... the FBR Capital Markets Annual,Spring Investor Conference, Thursday, May ... City., Steven G. Anderson, president and chief executive ... Time., CryoLife,s live presentation may be accessed through ...
... May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG,Pharmaceuticals, Inc. (Nasdaq: ... SSRX ), a,leading Chinese biotechnology company, ... commercialization agreement for ferumoxytol, an intravenous,iron replacement ... deficiency,anemia in chronic kidney disease (CKD) patients., ...
... May 27 CellCyte Genetics,Corporation (CellCyte) (OTC ... provide shareholders, potential investors and journalists,with accurate ... Room powered Web site: http://www.cellcyte.com ... or sources for stories from,CellCyte can access ...
Cached Biology Technology:CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference 2AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China 2AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China 3
(Date:8/27/2014)... willing to pay a premium for fruits, vegetables and ... the label claims is another matter. Now scientists studying ... to make sure farms are labelling their produce appropriately. ... Agricultural and Food Chemistry , could help prevent organic ... Food Safety Authority and the Wuerzburg University note that ...
(Date:8/27/2014)... studies have shown that excessive iron is ... disease. Previous studies from Chunyan Guo and ... have shown that baicalin prevented iron accumulation ... transporter 1 expression, and increased ferroportin 1 ... Parkinson,s disease rats. However, the relationship between ...
(Date:8/27/2014)... of Warwick research finds , Gamblers show the ... new research has shown. , Researchers, led by Dr ... Psychology, conducted tests that found that both human gamblers ... high-value than low-value rewards. , Published in Biology ... show the important role that memories of previous biggest ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2
... Unlike most of our sensory systems that detect only one ... detecting both chemical and mechanical stimuli to improve how we ... in the March issue of Nature Neuroscience. , This ... reaction in olfactory nerve cells, which control how our brain ...
... the University of Liverpool have found how two molecules fight ... , Researchers discovered that a large protein, which forms a ... secondary tumours, is attacked by a small protein that exists ... breast, lung and colorectal cancer, infected cells lose growth control ...
... onset of type 1 diabetes in mice prone to ... on the surface of immune T-cells. According to the ... January issue of the journal Diabetes, have significant implications ... More than 700,000 Americans have type 1 diabetes, an ...
Cached Biology News:Penn study on olfactory nerve cells shows why we smell better when we sniff 2Scientists discover how body fights to control spread of cancer 2Antibody therapy prevents type 1 diabetes in mice 2
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... synthetic peptide whose sequences are derived from mouse resistin protein. ... - S - M - P - L - C - ... - D - K - K - I - K - ... used for neutralization and control experiments with the polyclonal antibody that ...
... Imaging System, Basic Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
Biology Products: